Xin Lang Cai Jing·2025-08-27 01:29Group 1 - The core viewpoint of the article highlights that Fosun Pharma (600196.SH) reported strong financial performance in its 2025 mid-year report, ranking well among its peers in terms of revenue and profit growth [1][3] - The company's total operating revenue reached 19.514 billion yuan, ranking second among disclosed peers [1] - The net profit attributable to shareholders was 1.702 billion yuan, ranking third among disclosed peers, with a year-on-year increase of 477 million yuan, representing a growth of 38.96% compared to the same period last year [1] Group 2 - The operating cash flow net inflow was 2.134 billion yuan, ranking third among disclosed peers, with a year-on-year increase of 227 million yuan, achieving five consecutive years of growth, up 11.90% year-on-year [1] - The latest debt-to-asset ratio stands at 49.24% [3] - The latest gross profit margin is 48.12%, an increase of 0.35 percentage points from the previous quarter [3] Group 3 - The latest return on equity (ROE) is 3.59%, ranking 49th among disclosed peers, with an increase of 0.98 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.64 yuan, ranking 15th among disclosed peers, with an increase of 0.18 yuan, representing a growth of 39.13% year-on-year [3] - The latest total asset turnover ratio is 0.17 times, and the inventory turnover ratio is 1.45 times, ranking 33rd among disclosed peers, with a year-on-year increase of 0.06 times, up 3.99% [3] Group 4 - The number of shareholders is 230,000, with the top ten shareholders holding 1.663 billion shares, accounting for 62.27% of the total share capital [3] - The largest shareholder is Shanghai Fosun High Technology (Group) Co., Ltd., holding 33.32% [3]